Open AccessMetabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury
Author(s) -
Xu Li,
Pujun Gao,
Junqi Niu
Publication year - 2019
Publication title -
biomed research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 126
eISSN - 2314-6141
pISSN - 2314-6133
DOI - 10.1155/2019/8764093
Subject(s) - medicine , nonalcoholic fatty liver disease , metabolic syndrome , incidence (geometry) , diabetes mellitus , etiology , liver injury , fatty liver , comorbidity , obesity , disease , drug , bioinformatics , intensive care medicine , endocrinology , pharmacology , biology , physics , optics
The incidence and rates of diagnosis of drug-induced liver injury (DILI) have been increasing in recent years as findings from basic research and the examination of clinical databases reveal information about the clinical course, etiology, and prognosis of this complex disease. The prevalence of metabolic comorbidities (e.g., diabetes mellitus, fatty liver, obesity, and metabolic syndrome (MetS)) has been increasing during the same period. The results of preclinical and clinical research studies indicate that characteristics of metabolic comorbidities are also factors that affect DILI phenotype and progression. The objective of this review is to present the evidence for DILI and hepatotoxicity mechanisms, incidence, and outcomes in patients with MetS and nonalcoholic fatty liver disease. Moreover, we also summarize the relationships between drugs used to treat metabolic comorbidities and DILI.